Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costs

Onkologie

Volumn 33, Issue 12, 2010, Pages 658-664

  Eisele, Lewin ^a   Günther, Florian ^a   Ebeling, Peter ^a   Nabring, Jens ^a   Dührsen, Ulrich ^a   Dürig, Jan ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Acute myeloid leukemia; Febrile neutropenia; Outpatient treatment; Treatment costs

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; COLISTIN; COTRIMOXAZOLE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; SEROTONIN 3 ANTAGONIST;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE TOXICITY; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOPENIA; DIARRHEA; DRUG MEGADOSE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; INFECTION; INTENSIVE CARE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA AND VOMITING; OUTPATIENT CARE; RETROSPECTIVE STUDY; SYNCOPE;

ADULT; AGED; AMBULATORY CARE; ANEMIA, APLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BLOOD TRANSFUSION; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PATIENT DISCHARGE; PATIENT READMISSION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78649964789     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322209     Document Type: Article

References (28)

1. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M: Improved patient survival for acute myeloid leukemia: A population-based study of 9, 729 patients diagnosed in Sweden 1973-2005. Blood 2009;113:3666-3672.
2. Phekoo KJ, Richards MA, Moller H, Schey SA: The incidence and outcome of myeloid malignancies in 2, 112 adult patients in Southeast England. Haematologica 2006;91:1400-1404.
3. Stone RM, O'Donnell MR, Sekeres MA: Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004:98-117.
4. Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163.
5. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, Raffoux E, de Botton S, Pautas C, Reman O, Bourhis JH, Fenaux P, Castaigne S, Michallet M, Preudhomme C, de Revel T, Bordessoule D, Dombret H: Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129-5135.
6. Kohrt HE, Coutre SE: Optimizing therapy for acute myeloid leukemia. J Natl Compr Canc Netw 2008;6:1003-1016.
7. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, III: Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
8. Pulte D, Gondos A, Brenner H: Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008;93:594-600.
9. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R: Long-term outcome of highdose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-2982.
10. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk KM, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 2007;109:3658-3666.
11. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:217-223.
12. Gillis S, Dann EJ, Rund D: Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol 1996;51:26-31.
13. Girmenia C, Alimena G, Latagliata R, Morano SG, Celesti F, Coppola L, Spadea A, Tosti S, Mecarocci S, D'Elia GM, Tafuri A, Cimino G, Mandelli F: Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Haematologica 1999;84:814-819.
14. Halim TY, Song KW, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC: Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Ann Oncol 2007;18:1246-1252.
15. Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC: Shifting to outpatient management of acute myeloid leukemia: A prospective experience. Ann Oncol 2006;17:763-768.
16. Cole N, Gibson BE: High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia. Blood Rev 1997;11:39-45.
17. Prentice RL, Marek P: A qualitative discrepancy between censored data rank tests. Biometrics 1979;35:861-867.
18. Kleinbaum DG: Logistic regression. New York, Springer, 2002.
19. Lin MY, Weinstein RA, Hota B: Delay of active antimicrobial therapy and mortality among patients with bacteremia: Impact of severe neutro penia. Antimicrob Agents Chemother 2008;52:3188-3194.
20. Neuburger S, Maschmeyer G: Update on management of infections in cancer and stem cell transplant patients. Ann Hematol 2006;85:345-356.
21. Bishop JF: The treatment of adult acute myeloid leukemia. Semin Oncol 1997;24:57-69.
22. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH: Chemotherapy compared with auto logous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649-1656.
23. Rowe JM: Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program 2009:396-405.
24. Girmenia C, Russo E, Carmosino I, Breccia M, Dragoni F, Latagliata R, Mecarocci S, Morano SG, Stefanizzi C, Alimena G: Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and lowrisk febrile neutropenia. Ann Hematol 2007;86:263-270.
25. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL: Economic burden of acute myeloid leukemia: A literature review. Cancer Treat Rev 2004;30:237-247.
26. Katz LM, Howell JB, Doyle JJ, Stern LS, Rosenblatt LC, Piech CT, Zilberberg MD: Outcomes and charges of elderly patients with acute myeloid leukemia. Am J Hematol 2006;81:850-857.
27. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ: Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004;18:809-816.
28. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.